JACC Basic to Translational Science · 2021 · 26 citations · 24 references
MedicineCardiologyHematologyClinical CardiologyHemostasisInterventional CardiologyAcute Coronary SyndromesCoronary Artery DiseaseIschemic Heart DiseaseMicrovascular Dysfunction AssessmentPlatelet PhysiologyThrombosisCoronary Physiologic AssessmentFibrin Clot FormationMicrocirculatory DisturbanceMicrocirculatory FlowMicrocirculatory Flow ResistanceMyocardial Ischemic EventsThrombogenicity
The association between thrombogenicity and coronary microvascular dysfunction (CMD) has been poorly explored in patients with acute myocardial infarction (AMI). In our real-world clinical practice (N = 116), thrombogenicity was evaluated with thromboelastography and conventional hemostatic measures, and CMD was defined as index of microcirculatory resistance of >40 U using the invasive physiologic test. High platelet-fibrin clot strength (P-FCS) (≥68 mm) significantly increased the risk of postprocedural CMD (odds ratio: 4.35; 95% CI: 1.74-10.89). Patients with both CMD and high P-FCS had a higher rate of ischemic events compared to non-CMD subjects with low P-FCS (odds ratio: 5.58; 95% CI: 1.31-23.68). This study showed a close association between heightened thrombogenicity and CMD and their prognostic implications after reperfusion in acute myocardial infarction patients.
24
Fourth universal definition of myocardial infarction (2018)
Kristian Thygesen, Joseph S. Alpert, Allan S. Jaffe et al. · European Heart Journal · 2018 · 5.8K citations · Full text
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
John W. Eikelboom, Stuart J. Connolly, Jackie Bosch et al. · New England Journal of Medicine · 2017 · 2.4K citations · Full text
Coagulation abnormalities and thrombosis in patients with COVID-19
Marcel Levi, Jecko Thachil, Toshiaki Iba et al. · The Lancet Haematology · 2020 · 1.6K citations · Full text
Coronary Microvascular Dysfunction
Paolo G. Camici, Filippo Crea · New England Journal of Medicine · 2007 · 1.6K citations